NICE widens patient group for leukaemia drugBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7369.852/a (Published 19 October 2002) Cite this as: BMJ 2002;325:852
- Zosia Kmietowicz
The National Institute for Clinical Excellence (NICE) has recommended that anyone with chronic myeloid leukaemia who has failed first line therapy or is in the accelerated and blast phase of the disease should have access to the signal transduction inhibitor imatinib (Glivec). This is a wider group of patients than doctors and campaigners originally …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial